Small Molecules
22 November 2017
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting21 November 2017
Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments21 November 2017
Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK-002 for the Treatment of Myopia in Children21 November 2017
Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor21 November 2017
Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis21 November 2017
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse(R) in Ambulatory Patients with Spinal Muscular Atrophy (SMA)21 November 2017
Cytokinetics Announces Negative Results From VITALITY-ALS21 November 2017
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma20 November 2017
European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients20 November 2017
Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders20 November 2017
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer20 November 2017
Acorda Discontinues Tozadenant Development Program20 November 2017
FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for Topical Patidegib in Gorlin Syndrome20 November 2017
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children17 November 2017
Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck17 November 2017
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma16 November 2017
Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD15 November 2017
Preclinical Data Demonstrates Potential of Eidos Therapeutics’ Lead Compound for the Treatment for Transythyretin Amyloidosis15 November 2017
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance15 November 2017
Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia15 November 2017
Acorda Provides Update on Tozadenant Development ProgramNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports